Al-Salameh, 97 patient metformin prophylaxis study: 55% lower combined mortality/ICU admission [p=0.04] https://c19p.org/alsalameh
copied to clipboard
The association between metformin treatment and COVID-19 outcomes according to metformin continuation during hospitalisation
et al., Diabetes & Metabolism, doi:10.1016/j.diabet.2021.101297
Retrospective 140 diabetic patients in France, showing lower mortality for patients where metformin use was continued after hospitalization.
|
risk of death/ICU, 55.5% lower, RR 0.45, p = 0.04, treatment 9 of 47 (19.1%), control 22 of 50 (44.0%), NNT 4.0, adjusted per study, odds ratio converted to relative risk, metformin continued, multivariable.
|
|
risk of death/ICU, 68.4% higher, RR 1.68, p = 0.02, treatment 34 of 43 (79.1%), control 22 of 50 (44.0%), adjusted per study, odds ratio converted to relative risk, metformin discontinued, multivariable.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Al-Salameh et al., 11/30/2021, retrospective, France, Europe, peer-reviewed, 4 authors.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.